Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-468-3 | CAS number: 95-96-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Lactide (18:1 mixture of L-lactide and m-lactide) was tested in dogs in a 2 week dose range finding study and a subsequent 90d full study similar to OECD 408. The primary toxic effect was irritation of the gastrointestinal tract at 100 mg/kg/d in the 90d study. Lactide is a suitable read across partner as dilactide is a mixture of D- and L-lactide isomers.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Published study, meets generally accepted scientific standards and is described in sufficient detail. L-lactide is a suitable read across partner as dilactide is a mixture of D- and L-lactide isomers.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 409 (Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents)
- Deviations:
- not specified
- Principles of method if other than guideline:
- Doses for the 13-wk study were selected based on the results of a 2-week study. In the 13-wk study, four dogs per sex were assigned to each of four treatment groups (dosed with lactide at 0, 4, 20 and 100 mg/kg body weight/day). Each dog received daily oral doses of one to six gelatin capsules containing lactide. Doses were administered at approximately 1 hr after feed was withdrawn, and at approximately the same time each day for 13 weeks. Control dogs received the same number of empty capsules as dogs of the corresponding sex in the highest dose group. Doses were calculated based on the body weight of each dog during the previous week.
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Sprague Dawley, Inc ( Madison, WI, USA)
- Age at study initiation: ranged from 5 to 10 months
- Fasting period before study: 1 hour before dosing
- Housing: individual housed in stainless-stell cages on racks and were exercised at least twice weekly throughout the quarantine and study period
- Diet (e.g. ad libitum): dogs were fed Certified Canine Chow 5007 (PMI Feeds, Inc) for approximately 2 hours each day
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 26°C
- Humidity (%): 35 - 85%
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: capsule
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Each dog received daily oral doses of one to six gelatin capsules containing lactide. Doses were administered at approximately 1 h after feed was withdrawn, and at approximately the same time each day for 13 weeks.
Control dogs received the same number of empty capsules as dogs of the corresponding sex in the highest dose group. Doses were calculated based on the body weight of each dog during the previous week. - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- SIngle daily dose
- Remarks:
- Doses / Concentrations:
0, 4, 20, 100 mg/kg bw/d for 13 weeks.
Basis:
actual ingested - No. of animals per sex per dose:
- 4
- Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- Observations:
- Dogs were observed twice daily for mortality or moribundity.
- Cageside observations were performed daily, approximately 1 h after dosing.
- Once a week, each dog was removed from its cage and examined closely for detailed clinical signs of toxicity.
- Throughout each study:
dogs were weighed weekly, and food consumption was measured once a week over a 2-hour period.
Clinical pathology:
- blood and urine samples were obtained from each dog for clinical pathology and urinalysis determinations during quarantine, during week 5 and 9, and within 3 days prior to terminal sacrifice
Dogs were fasted overnight prior to blood collection for haematologic, clinical chemistry and coagulation analyses
Haematologic analyses included:
total leucocyte count, erythrocyte count, haemaglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelet count and differential leucocyte count. Reticulocyte counts and red blood cell morphology were evaluated.
Clinical chemistry analysis included:
By using a Roche Cobas Fara clinical chemistry analyser: blood urea nitrogen, creatinine, serum glucose, serum aspartate aminotransferase, serum alanine aminotransferase, alkaline phosphatase, glutamyl transferase, sodium, potassium, chloride, calcium, inorganic phosphate, total protein, albumin, albumin/total protein ratio, total bilirubin and cholesterol.
Coagulation analyses included:
Prothrombin time and activated partial prothrombin time, fibrinogen
Urine analyses included:
Urine specific gravity, urine microscopic sediment, urine pH, ketones, protein, glucose, bilirubin and occult blood - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- - Groups means and standard deviations for: body weights, food consumption, clinical pathology parameters, for terminal body weights and for absolute and relative organ weights
- Body weights, food consumption and clinical pathology parameters were evaluated by two-way repeated ANOVA, and if significant by Dunnett's test
- Mean body weights, mean organ weights and organ/body, organ:brain ratios for each treated group were compared to those of the control group by a two-tailed Student's t-test for each sex - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Emesis once in each of two female dogs (one in the 0 mg/kg and one in the 100 mg/kg group during week 9). Bloody diarrhoea was seen once during week 6 in one female dog of the 100 mg/kg group
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Emesis once in each of two female dogs (one in the 0 mg/kg and one in the 100 mg/kg group during week 9). Bloody diarrhoea was seen once during week 6 in one female dog of the 100 mg/kg group
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- stomach foci in one male/female from the 100 mg/kg , and one female from the 4mg/kg dose group
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- moderately severe ulceration of the stomach mucosa seen in one female dog of the high dose group
- Histopathological findings: neoplastic:
- no effects observed
- Dose descriptor:
- NOAEL
- Remarks:
- (systemic)
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LOAEL
- Remarks:
- (local)
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: gastrointestinal irritation
- Dose descriptor:
- NOAEL
- Remarks:
- (local)
- Effect level:
- 20 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Critical effects observed:
- not specified
- Conclusions:
- Lactide acts primarily, if not only, as an irritant after oral administration. 13 weeks NOAEL is 100 mg/kg bw/d.
- Executive summary:
In a subchronic toxicity study lactide (18:1 mixture of l-lactide and m-lactide) was administered to 4 beagle dogs/sex/dose by capsule at dose levels of 4, 20, 100 mg/kg bw/day for 13 weeks.
The only apparent toxic effect at 100 mg/kg/day was gastrointestinal irritation. Therefore, the local LOAEL is 100 mg/kg/d. No systemic effects were reported at 100 mg/kg/d. Thus, the systemic NOAEL for orally administered lactide under the conditions in this study was considered to be 100 mg/kg/day. Lactide is a suitable read across partner as dilactide is a mixture of D- and L-lactide isomers.
This subchronic study in dog is acceptable and satisfies the principle requirement for a subchronic oral study similar to OECD 409 in dog.
Reference
Table 1: Incidence of gross lesions in dogs treated for 13 weeks with oral doses of lactide | ||||||
Dose group | 0 mg/kg | 4 mg/kg | 20 mg/kg | 100 mg/kg | ||
Males | ||||||
Stomach focus | 0 | 0 | 0 | 1 | ||
Females | ||||||
Stomach focus | 0 | 1 | 0 | 1 |
Incidence= number of dogs in a given dose group with a given lesion. n=4 for all dose groups
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- dog
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Lactide is rapidly hydrolysed to lactic acid in water and in-vivo (gastric acid). Lactic acid is a ubiquitous and essential molecule of life. Lactate is non-toxic, any (local) effects are due to pH effects only.
In addition, in an oral toxicity (dose range finding) study, the read across partner lactide (18:1 mixture of L-lactide and m-lactide) was administered to beagle dogs by capsule at dose levels of 10, 100, 400, 1.000 and 2.500 mg/kg bw/day for 2 weeks, and 0, 4, 20 and 100 mg/kg/d for 13 weeks. The primary toxic effect of lactide in dogs was irritation of the alimentary tract. As irritating effects occurred down to a daily dose of 400 mg/kg bw (for 2 wks), the sub-chronic study was run with a maximum dose of 100 mg/kg bw/d.
At 1.000 and 2.500 mg/kg/d effects on body weight, and absolute and relative organ weights were reported in the 14-day dose range finding study for thymus and spleen. These effects were considered secondary to the irritation of the alimentary tract. In addition, a mild to moderate renal tubular regeneration was reported in all animals of the 2.500 mg/kg/d dose. Regeneration of the renal tubular epithelium is frequently seen as a reparative or adaptive change following tubular epithelial necrosis, and is suggestive of prior damage to this tissue. Although the mechanism of this effect is unknown, lactide toxicity cannot be excluded. Based on the possible renal toxicity the (systemic) LOAEL is 2.500 mg/kg bw/day. That's well above the limit dose of 1.000 mg/kg/d for a sub-acute toxicity study.
No systemic adverse effects were reported at the highest dose tested in the 90 d study (100 mg/kg/d). Therefore, the (systemic) NOAEL for orally administered lactide in a 90-d study in the dog is considered to be 100 mg/kg/day. The primary toxic effect after oral dosing was irritation of the gastrointestinal tract at 100 mg/kg/d. Lactide is a suitable read across partner as dilactide is a mixture of D- and L-lactide isomers.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Meets generally accepted scientific standards and is described in sufficient detail
Repeated dose toxicity: via oral route - systemic effects (target organ) digestive: other
Justification for classification or non-classification
Dilactide is to be considered non-toxic; the only effect are due to local irritation in the gastointestinal tract as a consequence of the formation of lacate derivates including lactoyl lactic acid and monomeric lactic acid. Therefore, based on the available data from the read across partner lactide, an 18:1 mixture of L-lactide and m-lactide, Dilactide does not warrant classification for repeated dose toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.